Get started
Author

Yulian P. Ramirez

Observed name: Yulian Ramirez
OpenAlex ID: A5110260853
Glioblastoma Multiforme Therapy and Mechanisms of Resistance
2013 · Yulian Ramirez, Jessica Weatherbee, et al. · Pharmaceuticals · 236
Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo
2015 · Georg Karpel-Massler, Chang Shu, et al. · Oncotarget · 53
PDF
Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth
2014 · Yulian P. Ramirez, Ann C. Mladek, et al. · Molecular Cancer Therapeutics · 26
PDF
Supplementary Figure Legends from Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth
2023 · Yulian P. Ramirez, Ann C. Mladek, et al.
Supplementary Figure S2 from Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth
2023 · Yulian P. Ramirez, Ann C. Mladek, et al.
Supplementary Figure S3 from Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth
2023 · Yulian P. Ramirez, Ann C. Mladek, et al.
Supplementary Figure S5 from Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth
2023 · Yulian P. Ramirez, Ann C. Mladek, et al.
Supplementary Figure S1 from Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth
2023 · Yulian P. Ramirez, Ann C. Mladek, et al.
Supplementary Figure S4 from Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth
2023 · Yulian P. Ramirez, Ann C. Mladek, et al.
Supplementary Figure Legends from Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth
2023 · Yulian P. Ramirez, Ann C. Mladek, et al.
Supplementary Figure S5 from Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth
2023 · Yulian P. Ramirez, Ann C. Mladek, et al.
Supplementary Figure S1 from Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth
2023 · Yulian P. Ramirez, Ann C. Mladek, et al.
Supplementary Figure S3 from Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth
2023 · Yulian P. Ramirez, Ann C. Mladek, et al.
Supplementary Figure S4 from Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth
2023 · Yulian P. Ramirez, Ann C. Mladek, et al.
Supplementary Figure S2 from Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth
2023 · Yulian P. Ramirez, Ann C. Mladek, et al.
Data from Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth
2023 · Yulian P. Ramirez, Ann C. Mladek, et al.
Data from Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth
2023 · Yulian P. Ramirez, Ann C. Mladek, et al.
Abstract 4476: Cytotoxicity of a novel bi-functional temozolomide analog, DP68, is independent of MGMT status in glioblastoma models.
2013 · Ann C. Mladek Tuma, Yulian Ramirez, et al. · Cancer Research
Abstract 963: Glioma treatment with temozolomide and Notch inhibition blocks tumor recovery through the induction of senescence and tumor clearance
2011 · Candace A. Gilbert, Yulian P. Ramirez, et al. · Cancer Research
Works count: 19
Citation count: 315
H-index: 3
I10-index: 3
Year
Topic
Type